Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetic Eye Problems Clear all
Completed No phase listed Observational

Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

NCT03112005
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
Interventions
Color fundus photography, Mydriatic Agent
Procedure · Drug
Lead sponsor
Eyenuk, Inc.
Industry
Eligibility
18 Years and older
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Jun 25, 2026, 5:24 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

NCT06270836
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Tarcocimab, Sham injection
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
38
States / cities
Tucson, Arizona • Fullerton, California • Glendale, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 25, 2026, 5:24 PM EDT
Not yet recruiting Not applicable Interventional

Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes

NCT06763952
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetes Mellitus
Interventions
AI
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
22 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 25, 2026, 5:24 PM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

NCT05607810
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
ADVM-022
Genetic
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Beverly Hills, California • Reno, Nevada • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Jun 25, 2026, 5:24 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Implementing Artificial Intelligence to Prevent Vision Loss From Diabetes

NCT07559292
View directory record Official record
Conditions
Vision Disorders, Diabetes
Interventions
AI, Usual Practice
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
22 Years and older
Enrollment
1,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 25, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.

NCT03238963
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 1467335, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Dothan, Alabama • Phoenix, Arizona • Beverly Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Jun 25, 2026, 5:24 PM EDT
Completed No phase listed Observational

Validation Study of RETINA-AI Galaxy™, an Automated Diabetic Retinopathy Screening Device

NCT04774822
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
Interventions
Color Fundus Photography, Mydriatics Agent, Optical Coherence Tomography (OCT)
Procedure · Drug
Lead sponsor
RETINA-AI Health, Inc.
Industry
Eligibility
22 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Jun 25, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

NCT01476449
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
2
States / cities
Clearwater, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Jun 25, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

ADVM-022 Intravitreal Gene Therapy for DME

NCT04418427
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Jun 25, 2026, 5:24 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

NCT03811561
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Coronado, California + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 25, 2026, 5:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

NCT04424290
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham control of BI 764524
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Jun 25, 2026, 5:24 PM EDT
Completed No phase listed Observational

Validation Study of RETINA-AI Galaxy™ v2.0, an Automated Diabetic Retinopathy Screening Device

NCT05368623
View directory record Official record
Conditions
Diabetes, Diabetic Retinopathy, Diabetic Macular Edema, Diabetic Eye Problems
Interventions
Color fundus photograph, Optical Coherence Tomography (OCT) of the retina, Mydriatic Agent
Diagnostic Test · Drug
Lead sponsor
RETINA-AI Health, Inc.
Industry
Eligibility
22 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jun 25, 2026, 5:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

NCT04429503
View directory record Official record
Conditions
Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
aflibercept, High-dose aflibercept
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
84
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 78 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Jun 25, 2026, 5:24 PM EDT